logo
Surgeon and Professor Is Deported to Lebanon Despite a Judge's Order

Surgeon and Professor Is Deported to Lebanon Despite a Judge's Order

New York Times16-03-2025

A kidney transplant specialist and professor at Brown University's medical school has been deported from the United States, even though she had a valid visa and a court order temporarily blocking her expulsion, according to her lawyer and court papers.
Dr. Rasha Alawieh, 34, a Lebanese citizen who had traveled to Lebanon last month to visit relatives, was detained on Thursday when she returned to the United States, according to a court complaint filed by her cousin Yara Chehab.
Judge Leo T. Sorokin of the Federal District Court in Massachusetts ordered the government on Friday evening to provide the court with 48 hours' notice before deporting Dr. Alawieh. But she was put on a flight to Paris, presumably on her way to Lebanon.
In a second order filed Sunday morning, the judge said there was reason to believe U.S. Customs and Border Protection had willfully disobeyed his previous order to give the court notice before expelling the doctor. He said he had followed 'common practice in this district as it has been for years,' and ordered the federal agency to respond to what he called 'serious allegations.'
A hearing in the case is scheduled for Monday.
Court documents related to the case were provided to The New York Times by Clare Saunders, a member of the legal team representing Ms. Chehab, who filed petitions to prevent her cousin's deportation, and then to request that her cousin be allowed to return to the United States.
Ms. Chehab's petitions name several members of the Trump administration as defendants, including Homeland Security Secretary Kristi Noem, Secretary of State Marco Rubio and the acting commissioner of Customs and Border Protection, Peter Flores.
Thomas Brown, a lawyer representing Dr. Alawieh and her employer, Brown Medicine, said that while the doctor was in Lebanon, the U.S. consulate issued her an H-1B visa, which allows highly skilled foreign citizens to live and work in the United States. Brown Medicine, a nonprofit medical practice, had sponsored her application for the visa.
According to Ms. Chehab's complaint, when Dr. Alawieh landed at Boston Logan International Airport on Thursday, she was detained by Customs and Border Protection officers and held at the airport for 36 hours, for reasons that are unclear.
Ms. Saunders said in an affidavit that she went to the airport Friday and notified Customs and Border Protection officials there — before the flight to Paris was scheduled to depart — that there was a court order barring the doctor's expulsion. She said that the officers there took no action and gave her no information until after the plane had taken off.
The agency did not immediately respond to a request for comment.
Dr. Alawieh graduated from the American University of Beirut in 2015. Three years later, she came to the United States, where she held medical fellowships at the Ohio State University and the University of Washington, and then worked as a resident at Yale.
Before the new visa was issued, she held a J-1 visa, the type commonly used by foreign students.
There is a shortage of American doctors working in Dr. Alawieh's area of specialty: organ transplants. The field is known for grueling, unpredictable work hours, with doctors often flying through the night to pick up donated organs before performing emergency surgery.
'It's very disruptive to family life,' said Dr. David Weill, a former director of Stanford's lung transplant program who is now a consultant to hospitals. Because many younger American physicians have growing concerns about work-life balance, 'a lot of hospitals are turning to talented doctors from outside the U.S. to get this work done,' Dr. Weill said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bargain Hunt expert jailed for selling art to suspected Hezbollah financier
Bargain Hunt expert jailed for selling art to suspected Hezbollah financier

Yahoo

timean hour ago

  • Yahoo

Bargain Hunt expert jailed for selling art to suspected Hezbollah financier

A former Bargain Hunt art expert has been jailed for two years and six months for failing to declare art he sold to a suspected financier of Hezbollah. In the first prosecution of its kind, Oghenochuko Ojiri, 53, admitted eight counts under the Terrorism Act 2000 of failing to make a disclosure during the course of business before his sentencing at the Old Bailey on Friday. Hezbollah is a group proscribed as a terrorist organisation by the UK. Judge Mrs Justice Cheema-Grubb said Ojiri had been aware the art he had sold was to Nazem Ahmad, who had been sanctioned in 2019 by the US authorities. "These offences are so severe that only a custodial sentence can be justified," she said. The judge said: "You knew about Ahmad's suspected involvement in financing terrorism and the way the art market can be exploited by people like him." "Your hard work, talent and charisma has brought you a great deal of success... you knew you should not have been dealing with that man," she told the court. Mrs Justice Cheema-Grubb said there was no evidence Ojiri supported any form of extremism but that his conduct undermined the detection of terrorist financing. Gavin Irwin, representing Ojiri, said the art expert's "humiliation is complete" with the star losing "his good name" and the "work he loves." "He'd like to apologise for undermining trust" in the art market, Mr Irwin said, adding Ojiri had been naïve. Profiting from an individual who funds terrorism is an extremely serious matter, said Cdr Dominic Murphy, head of the Metropolitan Police Counter Terrorism Command. "Raising money for terrorism is a core part of how terrorist groups are then able to cause harm around the world," he added. Ojiri's motivation appeared "to be financial along with a broader desire to boost his gallery's reputation within the art market by dealing with such a well-known collector," said Bethan David, head of the CPS Counter Terrorism Division. "This prosecution is believed to be the first of its kind, and the CPS will not hesitate to bring criminal charges against individuals who flout the law in this way." So how did an art expert, famous for appearing on UK daytime television get mixed up in funding Hezbollah? Financial investigators working in a specialised counter-terrorism unit at Scotland Yard had been tracking a series of suspicious transactions between the Middle East and London. Working with HMRC and colleagues in the Metropolitan Police's art and antiques unit, they focused on nine payments made in 2020 and 2021 by a man called Nazem Ahmad. He was sanctioned in 2019 by US authorities because he is believed to be a top donor to Lebanon-based Hezbollah, a Shia Muslim political and military group, which is backed by Iran and banned as a terrorist organisation by the US and UK. Hezbollah used Ahmad, who has joint Lebanese-Belgian nationality, "to launder substantial amounts of money bound for the terrorist group", according to the US Treasury department. It claims Ahmad has longstanding ties with the illegal trade in "blood diamonds", a reference to how diamonds are sometimes used to fund armed conflict and insurgencies. US authorities are offering a $10m reward for information about Ahmad, who is thought to still be in Lebanon. Authorities in the US claim Ahmad, 60, who has a vast art collection worth millions of pounds, opened an art gallery in his home city Beirut as a front to launder money. Transactions uncovered by UK police showed that Ahmad paid nearly £140,000 for works, which he had shipped from London to Dubai and Beirut. He bought them from Ojiri, including a £20,000 painting by Icelandic artist Baldur Helgason. Ojiri founded Ramp Gallery, now known as the Ojiri Gallery, based in east London. He came to public prominence with appearances in the BBC series Put Your Money Where Your Mouth Is, before hitting the big time on Bargain Hunt, in 2019. He has also appeared on Channel 5's Storage: Flog the Lot! In 2021, he joined Antiques Road Trip where he scoured antique shops for treasures, competing to make the most money at auction and always wearing one of his trademark hats. By this time, he had made several secret sales of art to the Hezbollah financier. Although he was careful to keep Ahmad's name off the paperwork, officers in the National Terrorist Financial Investigation Unit tracked the money to Ojiri and, in April 2023, police arrested him. On the same day the Treasury sanctioned Ahmad and banned him from travelling to the UK. The US authorities also charged Ahmad with defrauding the US and foreign governments, money laundering and sanctions evasion, claiming companies connected to him had been engaged in more than $400m worth of financial transactions between 2020 and 2022. As part of the American case, the Met police arrested a man living in Hayes, west London, for extradition to the US. Sundar Nagarajan is now awaiting trial in New York, accused of acting as Ahmad's accountant and advisor. At first, Ochuko Ojiri refused to answer police questions, but in a prepared statement he said he had no reason to believe Ahmad was a terrorist and money launderer. But evidence seized from his phone showed he had researched who Ahmad was and knew he had been sanctioned by the US. A colleague had even messaged to warn him against doing business with Ahmad. His arrest came after people working in the art market were brought into the regulated sector in 2019, meaning they were bound by anti-money laundering and terrorist financing measures to report suspicious transactions or face prosecution. Presented with such damning evidence, Ojiri said he was sorry for what he had done and told police he had wanted to grow his business. He denied being motivated by greed and said it was the kudos of dealing with a name in the collecting world. Ahmad's Instagram account had 200,000 followers at that time and he was seen as a social media influencer in the art world. Ojiri was charged under a section of the Terrorism Act 2000 that has never been used before. Police hope it will send a clear message to those doing business in the art world. "You will need to make sure you are doing your due diligence," Cdr Murphy said. Last year, the National Crime Agency issued an amber alert warning that storage facilities for artwork could be used by criminals "seeking a capital asset that can be safely stored, that appreciates in value over time, and that can be liquidated if and when required". It followed the seizure of 23 paintings, worth almost £1m, from a warehouse and an auction house in London. The art, which included work by Pablo Picasso and Andy Warhol, belonged to Ahmad. It will soon be sold off at auction as the proceeds of crime and the money raised will go to the Home Office to be used in the fight against crime.

JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website

Yahoo

timean hour ago

  • Yahoo

JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website

- A refreshed global brand signals JCR's expanded international presence and unwavering focus on rare and genetic diseases worldwide - HYOGO, Japan, June 06, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. "At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world," said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. "In September, we celebrate the 50th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases." The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: View source version on Contacts Investors & Media:JCR Pharmaceuticals Co., Communicationsir-info@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Omada Health goes public at $23 per share, marking second major digital health IPO in 2025
Omada Health goes public at $23 per share, marking second major digital health IPO in 2025

Yahoo

timean hour ago

  • Yahoo

Omada Health goes public at $23 per share, marking second major digital health IPO in 2025

Omada Health (OMDA) has become the second major digital health company to debut on the public markets this year, with an initial public offering valued at $1.1 billion. The company follows a successful launch of Hinge Health (HNGE) last month, which plays in one of the same markets as Omada: musculoskeletal health guidance. But Omada is better known as a clinical health guidance company for multiple chronic diseases, with an emphasis lately on weight loss management. Omada began trading at $23 per share on the Nasdaq on Friday. By midday, Omada stock traded as high as $28 per share, up 47% from the $19 per share the stock was initially priced at. Read more about Omada's opening stock moves and today's market action. The digital health platform has found its footing in the weight management space, though not by offering popular GLP-1 treatments. The company doesn't plan on doing so in the future either, CEO Sean Duffy told Yahoo Finance. Duffy said that's one reason why "the capital markets have, in many ways, asked us to come in" to the public markets. The company has differentiated itself and avoided the pitfalls of an ever-changing GLP-1 market, which was plagued early on by shortages and then disruption after the FDA removed GLP-1s from its shortage list, ending access to copycats of the popular drugs. Omada provides clinical guidance to patients once they leave their doctor's office. It's a concept that Duffy and his co-founders realized was needed more than a decade ago when the weight loss market and technology were very different. When asked if Duffy regretted not going public during the pandemic, when digital health was experiencing an investment boom, he said no and added that the company had only begun expanding beyond diabetes into other care areas, including weight loss. "When you're becoming a public company, you want to make sure to have your proof points out there," Duffy said. "In retrospect, it was a great decision." But Omada does have the pandemic to thank for its growth, as it put a spotlight on digital health services. The company has grown its user base through partnerships with large companies that offer the services to employees. In addition, Omada is partnered with pharmacy benefit managers, including CVS (CVS) and Cigna (CI) — the latter of which is also an early investor through its ventures arm. Omada began its journey by serving the needs of diabetics, including a partnership with Abbott (ABT) and users of its Freestyle Libre continuous glucose monitoring devices. It has since expanded to the GLP-1 market by providing the same guidance services, including meal kits and lifestyle change advice, to patients. Still, the company has yet to turn a profit in its 14-year existence. Duffy said the company's losses are decreasing over time, and revenue continues to grow year over year. "We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis," the company said in its S-1 filing. The company stated it incurred net losses of $67.5 million and $47.1 million in 2023 and 2024, respectively. In the first quarter ended March 31 of this year, Omada lost $9.4 million compared to a $19 million loss in the same period a year prior. "We incurred net losses of $67.5 million and $47.1 million for the years ended December 31, 2023 and 2024, respectively, and $19.0 million and $9.4 million for the three months ended March 31, 2024 and 2025, respectively." Duffy said he hopes new investors can help guide the company to become a leading platform addressing chronic disease. "It's just a neat moment in time, where the new shareholders that are coming in can help me, and help us, imagine a path ... to bend the curve of disease," he said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store